Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Breakthrough Designation Is A Two-Way Street, FDA Cautions Sponsors

Executive Summary

Sponsors of would-be breakthrough therapies need to move as quickly as FDA is acting, from responding to emails to ramping up manufacturing so they can start trials earlier.


Related Content

Breakthrough Designation Can Be 'Lever' For Manufacturing Evolution, FDA Says
Faster EU Drug Assessment Pathway Could Launch In First Quarter 2016
‘Breakthrough’ Fee Eyed As Deterrent To Frivolous Requests
‘Breakthrough’ Drugs Get ‘Road-MaPP’ – Complete With Communication Timetable
“Breakthrough” Therapies: Pharmacyclics Gains More Access, Certainty For Ibrutinib


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts